Brooks, M.D., Centers for Disease Control and Prevention; Mary Jane Burton, M.D., University of Mississippi Medical Center; Adeel A. Butt, M.D., M.S.,
University of Pittsburgh School find protocol of Medicine; Raymond T. Chung, M.D., Harvard Medical School Massachusetts General Hospital; Timothy J. Davern, M.D., University of California at San Francisco; Carmen de Mendoza, Ph.D., University Complutense Hospital Carlos III; Matthew J. Dolan, M.D., F.A.C.P., San Antonio Military Medical Center (SAMMC); Joseph Etienne, M.D., Louisiana State University; Judith Feinberg, M.D., University of Cincinnati College of Medicine; Russell D. Fleischer, PA-C, M.P.H., US Food and Drug Administration; Marshall J. Glesby, M.D., Ph.D., Weill Cornell Medical College; Zachary D. Goodman, M.D., Ph.D., Armed Forces Institute of Pathology; Richard M. Green, M.D., Northwestern University Feinberg School of Medicine; Gobuiwang K. Kurusa, M.D., St. Michael’s Medical Center; Sharon Lieberman, PharmD, Bronx VA Medical Center; Kristen M. Marks, M.D., Weill Cornell Medical College; Christina Martin, B.Sc., University of Cincinnati College of Medicine; Craig J. McClain, M.D., University of Louisville; Barbara H. McGovern, M.D., Tufts University School of Medicine Lemuel Shattuck Hospital; Sabeen Munib, M.D., AIDS
Healthcare Foundation; Margaret V. Ragni, M.D., M.P.H., University of Pittsburgh Medical Center; Stuart Ray, M.D., find more Johns Hopkins University School of Medicine; David Rhimland, M.D., VA Medical Center; Jeffrey H. Samet, M.D., M.A., M.P.H., Boston CH5424802 mouse University
School of Medicine, Boston Medical Center; Amy Shah, M.D., Virginia Commonwealth University; Richard K Sterling, Virginia Commonwealth University Health System; Peter G. Stock, M.D., Ph.D., University of California at San Francisco; Paula Tuma, M.D., University Complutense Hospital Carlos III; Eugenia Vispo, M.D., University Complutense Hospital Carlos III; and Philippe J. Zamor, M.D., University of Cincinnati College of Medicine. “
“Background and Aim: Although functional gastrointestinal (GI) disorders has been paid more attention recently in Japan, similar to Western countries, the clinical characteristics of dyspeptic patients, current diagnostic approach to dyspeptic patients and current standard treatments for dyspeptic patients are not well known in Japan. This review, in the most part, summarizes two topics about Japanese dyspeptic patients. The first topic is the pros and cons of the diagnosis of Japanese dyspeptic patients using Rome III classification on the basis of our data and the second topic deals with standard treatments for dyspeptic patients–especially by primary care doctors in Japan. Methods: We conducted a PubMed search using the following key words alone or in combination: functional dyspepsia (FD), medical treatment, Rome III classification and Japanese.